Pressure mounts on silicone breast implants:
This article was originally published in Clinica
Executive Summary
Seven leading Congressmen have written to FDA Commissioner David Kessler urging him to comment on US and international studies of silicone implant safety and to reassure women. So far, he has refused. Commenting on the British health authoritys' statement discounting a link between silicone breast implants and connective tissue diseases, an FDA spokesman said: "We are encouraged by recent studies showing that the immune-disease problem is smaller than we believed .... But the studies are not definitive. Nothing has been said about [implant] breakage and migration (of silicone within the body)."
You may also be interested in...
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.